Summit Therapeutics's total assets for Q2 2025 were $324.04M, a decrease of -15.58% from the previous quarter. SMMT total liabilities were $64.60M for the fiscal quarter, a 63.57% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.